Exicure (Exicure) Deferred Tax : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Exicure Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Exicure's change in deferred tax for the three months ended in Sep. 2023 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Exicure Deferred Tax Historical Data

The historical data trend for Exicure's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Deferred Tax Chart

Exicure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Deferred Tax

Get a 7-Day Free Trial

Exicure Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Exicure Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Exicure Deferred Tax Related Terms

Thank you for viewing the detailed overview of Exicure's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Exicure (Exicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

2H0A:Germany 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Executives

Minhee Eom	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd.	10 percent owner	23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim	director, officer: Chief Executive Officer, CFO	46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller	director, officer: Chief Executive Officer, CFO	2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang	director	C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo	director	2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul	director	2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn	director	2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc.	10 percent owner	3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077